In addition, despite early diagnosis, around 20% of patients with ER-positive and HER2-negative BC experience disease recurrence within the first decade, and this persistent risk highlights the need for novel therapeutic strategies, particularly for those with high-risk disease [26]. Here, ERBB2 is linked to breast cancer.